BeiGene 8-K Signals Officer/Director Changes, Comp Arrangements
Ticker: BEIGF · Form: 8-K · Filed: Jan 23, 2024 · CIK: 1651308
| Field | Detail |
|---|---|
| Company | Beigene, LTD. (BEIGF) |
| Form Type | 8-K |
| Filed Date | Jan 23, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $400,000, $65,000, $17,500 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-changes, compensatory-arrangements, corporate-governance
TL;DR
**BeiGene filed an 8-K on Jan 23rd, signaling executive changes and compensation updates.**
AI Summary
BeiGene, Ltd. filed an 8-K on January 23, 2024, reporting an event that occurred on January 22, 2024. This filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers' and 'Financial Statements and Exhibits'. While the specific details of these changes are not provided in this excerpt, such filings often signal shifts in leadership or executive compensation, which can impact a company's strategic direction and financial health. Investors should pay attention to the full details of these changes as they can influence future performance and stock valuation.
Why It Matters
Changes in leadership or executive compensation can significantly alter a company's strategy, operational efficiency, and financial outlook, directly impacting shareholder value.
Risk Assessment
Risk Level: medium — The filing indicates changes in leadership or compensation, which can introduce uncertainty or signal strategic shifts, warranting investor attention.
Analyst Insight
Investors should seek out the full text of the 8-K to understand the specific personnel and compensation changes, as these details will inform the potential impact on BeiGene's future strategy and financial performance.
Key Numbers
- 13 — Ordinary Shares per American Depositary Share (defines the conversion ratio for American Depositary Shares)
- $0.0001 — Par value per Ordinary Share (fundamental value of each ordinary share)
Key Players & Entities
- BeiGene, Ltd. (company) — the registrant filing the 8-K
- Cayman Islands (company) — jurisdiction of incorporation for BeiGene, Ltd.
- NASDAQ Global Select Market (company) — exchange where BeiGene's American Depositary Shares are registered
- The Stock Exchange of Hong Kong Limited (company) — exchange where BeiGene's Ordinary Shares are registered
- $0.0001 (dollar_amount) — par value per Ordinary Share
Forward-Looking Statements
- The full 8-K filing will disclose the names of departing or newly appointed officers/directors. (BeiGene, Ltd.) — high confidence, target: N/A
- The filing will detail changes to executive compensation packages. (BeiGene, Ltd.) — high confidence, target: N/A
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 22, 2024.
What specific items of information are included in this 8-K filing?
This 8-K filing includes information under 'Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers' and 'Item 9.01 Financial Statements and Exhibits'.
Where are BeiGene, Ltd.'s American Depositary Shares traded?
BeiGene, Ltd.'s American Depositary Shares, each representing 13 Ordinary Shares, are traded on The NASDAQ Global Select Market under the trading symbol BGNE.
What is the par value of BeiGene, Ltd.'s Ordinary Shares?
The par value of BeiGene, Ltd.'s Ordinary Shares is $0.0001 per share.
What is BeiGene, Ltd.'s Commission File Number?
BeiGene, Ltd.'s Commission File Number is 001-37686.
Filing Stats: 1,383 words · 6 min read · ~5 pages · Grade level 11 · Accepted 2024-01-23 06:03:37
Key Financial Figures
- $0.0001 — resenting 13 Ordinary Shares, par value $0.0001 per share BGNE The NASDAQ Global Sele
- $400,000 — . Brandicourt share options valued at US$400,000, pro-rated in the first year of service
- $65,000 — o receive annual cash compensation of US$65,000 for his service as a director, and annu
- $17,500 — ctor, and annual cash compensation of US$17,500 for his service as a member of the Audi
Filing Documents
- bgne-20240122.htm (8-K) — 42KB
- a20240123formxmalleyresign.htm (EX-99.1) — 15KB
- 0001651308-24-000005.txt ( ) — 189KB
- bgne-20240122.xsd (EX-101.SCH) — 2KB
- bgne-20240122_lab.xml (EX-101.LAB) — 24KB
- bgne-20240122_pre.xml (EX-101.PRE) — 13KB
- bgne-20240122_htm.xml (XML) — 3KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press release titled "BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors" issued by BeiGene, Ltd. on January 23, 2024 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL Exhibit Index Exhibit No. Description 99.1 Press release titled "BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors" issued by BeiGene, Ltd. on January 23, 2024 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BEIGENE, LTD. Date: January 23, 2024 By: /s/ Chan Lee Name: Chan Lee Title: Senior Vice President, General Counsel